Related Experiment Video
Updated: Dec 28, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
Renata Marietta Bocskei1,2, Martina Meszaros1, Adam Domonkos Tarnoki3
1Department of Pulmonology, Semmelweis University, 1083 Budapest, Hungary.
Soluble urokinase-type plasminogen activator receptor (suPAR) levels did not differ between obstructive sleep apnoea (OSA) patients and controls. suPAR is not significantly involved in OSA pathophysiology, though higher levels were observed in women.
Area of Science:
- Sleep Medicine
- Inflammation Research
- Biomarker Discovery
Background:
- Obstructive sleep apnoea (OSA) is linked to systemic inflammation and hypercoagulation.
- Soluble urokinase-type plasminogen activator receptor (suPAR) influences fibrinolysis and inflammation.
- The role of suPAR in OSA has not been previously studied.
Purpose of the Study:
- To investigate plasma suPAR levels in patients with obstructive sleep apnoea (OSA).
- To determine if suPAR levels correlate with OSA severity or related comorbidities.
Main Methods:
- Study included 53 OSA patients and 15 healthy controls.
- In-hospital polysomnography was performed for OSA assessment.
- Plasma suPAR concentrations were measured using ELISA.
Main Results:
- No significant difference in plasma suPAR levels was found between OSA patients and controls.
- suPAR levels did not correlate with OSA severity, blood results, or comorbidities.
- Plasma suPAR levels were significantly higher in women compared to men across all subjects.
Conclusions:
- suPAR does not appear to play a significant role in the pathophysiology of OSA.
- A notable gender difference in suPAR levels was observed, requiring consideration in future research.
More Related Videos
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Peripheral Artery Disease I: Introduction
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: